SGMT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SGMT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sagimet Biosciences's Accounts Payable for the quarter that ended in Sep. 2024 was $1.15 Mil.
Sagimet Biosciences's quarterly Accounts Payable increased from Mar. 2024 ($0.53 Mil) to Jun. 2024 ($1.99 Mil) but then declined from Jun. 2024 ($1.99 Mil) to Sep. 2024 ($1.15 Mil).
Sagimet Biosciences's annual Accounts Payable increased from Dec. 2021 ($0.76 Mil) to Dec. 2022 ($1.13 Mil) but then declined from Dec. 2022 ($1.13 Mil) to Dec. 2023 ($0.19 Mil).
The historical data trend for Sagimet Biosciences's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Accounts Payable | 1.20 | 0.51 | 0.76 | 1.13 | 0.19 |
Sagimet Biosciences Quarterly Data | ||||||||||||||||
Dec19 | Mar20 | Dec20 | Mar21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Accounts Payable | Get a 7-Day Free Trial | 1.70 | 0.19 | 0.53 | 1.99 | 1.15 |
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Thank you for viewing the detailed overview of Sagimet Biosciences's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
George Kemble | director | SAGIMET BIOSCIENCES INC., 155 BOVET RD., STE. 303, SAN MATEO CA 94402 |
Elizabeth Rozek | officer: General Counsel and CCO | SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO CA 94402 |
Eduardo Bruno Martins | director | 350 CAMBRIDGE AVE, SUITE 350, PALO ALTO CA 94306 |
David Happel | director, officer: President & CEO | 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
New Enterprise Associates 13 Lp | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Beth C Seidenberg | director | |
Nea 13 Gp, Ltd | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Jinzi Jason Wu | director | SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO CA 94402 |
Dennis Hom | officer: Chief Financial Officer | C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080 |
Kpcb Pbd Associates, Llc | 10 percent owner | C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025 |
Kpcb Pandemic & Bio Defense Fund Llc | 10 percent owner | 2750 SAND HILL RD, MENLO PARK CA 94025 |
Nea Partners 13, Limited Partnership | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Elizabeth A Grammer | director | 78TH FOURTH AVENUE, WALTHAM MA 02451 |
Anthony M Rimac | officer: Chief Operating Officer | C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE CA 94608 |
Patrick J Kerins | 10 percent owner |
From GuruFocus
By Marketwired • 10-18-2023
By GlobeNewswire • 01-23-2024
By Marketwired • 08-21-2023
By Marketwired • 11-18-2024
By Marketwired • 09-27-2023
By Marketwired • 10-24-2023
By Marketwired • 10-01-2024
By Marketwired • 05-06-2024
By Marketwired • 04-22-2024
By GuruFocus News • 11-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.